REGENXBIO, Inc. (RGNX)
9.60
+0.28
(+3.00%)
USD |
NASDAQ |
Sep 02, 16:00
9.75
+0.15
(+1.56%)
Pre-Market: 09:18
REGENXBIO Research and Development Expense (Annual) : 212.68M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 212.68M |
| December 31, 2024 | 192.31M |
| December 31, 2023 | 214.95M |
| December 31, 2022 | 229.54M |
| December 31, 2021 | 171.87M |
| December 31, 2020 | 157.89M |
| December 31, 2019 | 117.03M |
| Date | Value |
|---|---|
| December 31, 2018 | 83.87M |
| December 31, 2017 | 57.22M |
| December 31, 2016 | 45.48M |
| December 31, 2015 | 17.28M |
| December 31, 2014 | 4.961M |
| December 31, 2013 | 5.051M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| AbbVie, Inc. | 8.249B |
| Capricor Therapeutics, Inc. | 83.50M |
| Biogen, Inc. | 1.481B |
| United Therapeutics Corp. | 550.00M |
| Ardelyx, Inc. | 68.47M |